Kolinpharma SpA
MIL:KIP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Mask Investments Ltd
NSE:MASKINVEST
|
IN |
Kolinpharma SpA
Revenue
Kolinpharma SpA
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kolinpharma SpA
MIL:KIP
|
Revenue
€14.1m
|
CAGR 3-Years
16%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Intercos SpA
MIL:ICOS
|
Revenue
€1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Pharmanutra SpA
MIL:PHN
|
Revenue
€180.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Enervit SpA
MIL:ENV
|
Revenue
€103.2m
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Kolinpharma SpA
Glance View
Kolinpharma SpA engages in the research, development, and marketing of food supplements based on natural raw materials of natural origin. The company is headquartered in Lainate, Milano and currently employs 110 full-time employees. The company went IPO on 2018-03-09. The firm offers a number of products, including almetax, which is a food supplement based on alpha-lipoic acid, L-tryptophan, turmeric, vitamins B5, b6 AND C, Chromium picolinade and Zinc that acts synergistically on the main symptoms of menopause; Almatex easy, which enables the preservation of the general well-being of the body; Dolasix, which is a food supplement that acts synergistically in favor of the normal functionality of cartilages and connective tissues; Ivuxur, which is a food supplement based on cranberry ( dried cranberry extract), D-mannose, bearberry and Zinc that is used in the treatment of unary tract infections; Milesax, which is a food supplement based on magnesium bisglycinate, boswellia serrata and L-tryptophan that acts synergistically on contractures, muscles relaxation and mood during the rehabilitation and recovery phases, and Xinepa, among others.
See Also
What is Kolinpharma SpA's Revenue?
Revenue
14.1m
EUR
Based on the financial report for Dec 31, 2022, Kolinpharma SpA's Revenue amounts to 14.1m EUR.
What is Kolinpharma SpA's Revenue growth rate?
Revenue CAGR 5Y
28%
Over the last year, the Revenue growth was 26%. The average annual Revenue growth rates for Kolinpharma SpA have been 16% over the past three years , 28% over the past five years .
